FDA Grants Lannett (LCI) Approval for Hydrochlorothiazide Capsules, 12.5 mg

Lannett Company, Inc. (NYSE: LCI) today announced it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Hydrochlorothiazide Capsules, 12.5 mg. Hydrochlorothiazide Capsules, 12.5 mg, is therapeutically equivalent to the reference listed drug, Microzide Capsules, 12.5 mg, of Watson Pharmaceuticals. Sales of Hydrochlorothiazide Capsules, 12.5 mg, at Average Wholesale Price were approximately $204 million for the 12 months ending October 2011, according to Wolters Kluwer. Shipping is expected to commence shortly.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Radiopharm trial advances to higher dose in HER2+ cancer study
• Ionis to present olezarsen and ION775 data at ESC Congress 2026